Publication

Elafibranor and liraglutide improve differentially liver health and metabolism in a mouse model of non-alcoholic steatohepatitis

Liver International 41(8):1853-1866, 2021

Perakakis N, Stefanakis K, Feigh M, Veidal SS, Mantzoros CS

Share this page

Resource Library

Related resources

Disease progression in the non-obese CDAA-HFD mouse model of advanced NASH and fibrosis

Bariatric surgery in patients with non-alcoholic fatty liver disease – from pathophysiology to clinical effects

Metabolic, biochemical and histological characterization of a CDAA-HFD-induced non-obese rat model of advanced NASH with progressive fibrosis

Preclinical efficacy and clinical translatability of elafibranor in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH

For further information

Contact us

Gubra

Hørsholm Kongevej 11B
2970 Hørsholm
Denmark

+45 3152 2650